Alerta

一类可离子化脂质分子、其组合物与应用

Resumen de: CN120093932A

本发明属于药物载体技术领域，涉及一类可离子化脂质分子、其组合物与应用。该脂质分子包括通过可水解的酯键间接连接氨基酸结构部分和生育酚脂质结构部分，其中，可离子化基团为氨基酸结构部分的碱性基团。在优选的实施例中，间接连接氨基酸结构部分与生育酚脂质结构部分为亚烷基醚；氨基酸结构部分为赖氨酸、组氨酸、精氨酸，或及其衍生物的残基。本发明还公开了包括一种或多种可离子化脂质分子与治疗剂或预防剂制成的组合物，以及该脂质分子或组合物在制备核酸药物、小分子药物、多肽或蛋白质药物中的应用，其中，所制备的负载RNA脂质纳米粒，可在体内表达或沉默蛋白，具有稳定性好、转染效率高、毒性低、安全有效等优点。

一种侧链含功能性基团的阳离子脂质及其应用

Resumen de: US2025034080A1

A novel type of cationic lipid and PEGylated derivative thereof, a cationic liposome and a cationic liposome-nucleic acid pharmaceutical composition containing the cationic lipid and formulation thereof include an ionizable lipid compound of the general formula (1). This compound is slightly ionized or neutral at physiological pH but undergoes greater ionization under acidic conditions, exhibiting lower toxicity in the systemic circulation and improved endosomal escape ability. The compound's polar head contains an ionizable tertiary amine group along with a side chain containing functional groups, while the tail chains may include linking groups that are easily degraded. Cationic liposomes containing the compound have a better ability to complex with nucleic acid drugs, higher stability in serum, no apparent cytotoxicity, and high transfection efficiency.

用于递送包括核酸的活性剂的组合物和方法

Resumen de: AU2023329918A1

Disclosed herein are lipid nanoparticles for the delivery of active agents, including nucleic acids, as well as methods of making using thereof.

一种香叶木素纳米结构脂质载体及其制备方法和用途

Resumen de: CN120093711A

本发明公开了一种香叶木素纳米结构脂质载体，它由以下重量配比的原料制成：香叶木素5‑10%；脂质材料50‑70%；甘露糖修饰的胆固醇8‑20%；乳化剂15‑25%，属于生物医药领域。本发明通过制备纳米结构脂质载体提高了香叶木素的稳定性，延缓了药物在体内的释放速度，提高了血药浓度和生物利用度，并且还提高了药物的肺部靶向性，降低了药物的细胞毒性，在非小细胞肺癌的临床治疗中有很好的应用前景。

用于核酸的器官特异性递送的组合物和方法

Resumen de: US2024245620A1

The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.

一种自驱动微型机器人双载药系统、其制备方法及应用

Resumen de: CN120093671A

本发明涉及一种自驱动微型机器人双载药系统、其制备方法及应用，属于医药技术领域。自驱动微型机器人双载药系统由PLGA微针和覆盖PLGA微针上的泡腾底座构成；其中，PLGA微针的针腔里面镶嵌着自驱动蛋壳微颗粒和叠氮化外泌体的连接体，泡腾底座中包裹着血管内皮生长因子脂质颗粒。本发明提供的自驱动微型机器人双载药系统，能够巧妙地利用介质中的能量源自主移动，这一特性使其在疾病部位直接装载、运输和递送治疗药物成为可能，显著提升了治疗效果，并大幅降低了高度毒性药物的全身副作用。

射线响应型自组装多肽、其水凝胶和应用

Resumen de: CN120098070A

本发明属于生物医药领域，具体涉及射线响应型自组装多肽、其水凝胶和应用。本发明的射线响应型自组装多肽衍生物水凝胶具有合成方法简单、生物相容性好、易于负载药物等优点。该水凝胶能够通过射线响应触发脉冲式药物释放，时空可控地精确调控药物的释放速率，增强放疗与药物治疗的协同效果。由于其高生物安全性，可避免对人体的长期负面影响，具有非常广阔的应用前景。因此，本发明的射线响应型多肽水凝胶可广泛应用于肿瘤放疗联合治疗、术后组织修复与再生、核药递送及核医学影像引导的治疗等与放射相关的疾病治疗中，提供更加精准和有效的协同治疗方案。

一种具有光热-光动力-气体协同杀菌性能的纳米粒子及其应用

Resumen de: CN120093913A

本发明提供一种多功能抗菌纳米粒子，所述抗菌纳米粒子为包含以下组分(A)至(C)的原料组合物的交联产物：(A)如下式(I)所示的醌式共轭有机分子：#imgabs0#(B)两亲性含醛基嵌段共聚物；和，(C)L‑精氨酸。本发明的抗菌纳米粒子基于“光热杀菌‑光动力杀菌‑气体杀菌”原理协同作用根除细菌，具有良好的抗菌、消除细菌生物膜及促进伤口恢复作用，尤其适合针对耐药菌感染如耐甲氧西林葡萄球菌(MRSA)感染的治疗。

PLATINUM-BASED AMPHIPHILE PRODRUGS

Resumen de: US2025177345A1

The present invention relates to platinum (IV) prodrug lipid-based amphiphiles and compositions thereof. In particular, it relates to cisplatin, oxaliplatin and carboplatin prodrugs with the capacity to make stable liquid crystalline nanoparticles and crystalline nanoparticles, and uses thereof to treat cancer in animals, including human.

TRANSMEMBRANE STEM CELL FACTOR (TM-SCF) LIPID NANOCARRIERS AND METHODS OF USE THEREOF

Resumen de: US2025177483A1

The present invention relates to compositions comprising transmembrane stem cell factor (tmSCF) lipid nanocarriers and methods of use thereof.

COLOR-CHANGING ANTIBACTERIAL NANOFIBER MEMBRANE AND METHOD

Resumen de: US2025177319A1

A bacteria-responsive color-changing, core-shell nanofiber, comprising polyurethane (PU), a hemicyanine-based chromogenic probe localized in the core-shell nanofiber near the surface of the shell, polyvinylpyrrolidone (PVP) dopant in the shell, the hemicyanine-based chromogenic probe further comprising a labile ester linkage that is enzymatically cleavable by bacterial lipase released from clinically relevant strains of bacteria including Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA).

SELECTIVE AGONISM OF SPECIFIC PATTERN RECOGNITION RECEPTORS IN mRNA CONSTRUCTS FOR SAFE, EFFECTIVE AND DURABLE VACCINES

Resumen de: US2025177317A1

A lipid nanoparticle based composition and method for making the same is provided. The lipid nanoparticle based composition includes an in-vitro transcribed (IVT) mRNA molecule containing (a) a 5′ cap structure, (b) a coding region encoding an antigen polypeptide, (c) an immunostimulatory RNA sequence that activates RIG-I, (d) a poly (A) tail, and (e) a TLR antagonist based on a phospholipid.

METHODS AND COMPOSITIONS FOR TREATING STROKE

Resumen de: US2025177437A1

Some embodiments include methods of treating, inhibiting, or ameliorating ischemic stroke or a symptom thereof in a subject. Some embodiments include oxygenated fluid for use in treating, inhibiting, or ameliorating ischemic stroke. The oxygenated fluid may comprise charge-stabilized oxygen-containing nanostructures.

RNA MOLECULES AND COMPOSITIONS FOR CANCER IMMUNOTHERAPY

Resumen de: US2025177432A1

This disclosure provides compositions and methods for treating cancers. The compositions include mRNA molecules encoding proteins useful for treating the cancers, such as IL-12, an OX40 agonist, and optionally along with FADD, MLKL or MLKL-4HB. The mRNA can include 5′UTR and 3′UTR sequences and 5′cap structures that improve the stability and/or therapeutic effects of these mRNA molecules.

TRIPLEX NANOPARTICLES

Resumen de: US2025177301A1

A multi-layer (multi-lamellar) coated nanoparticle is provided wherein the nanoparticle comprises a first coat comprising a positively charged polymer or a positively charged lipd bilayer and a second coat comprising an anionic bilayer and optionally one or more distinct cargo molecules, one or more distinct targeting moieties, or any combination thereof, as well as methods of making and using the nanoparticle.

NANOPARTICLE DISPERSIONS COMPRISING THERAPEUTIC AGENTS

Resumen de: AU2023385865A1

Disclosed herein are dense nanolipid fluid (DNLF) dispersions comprising desirable characteristics for incorporating bioactive agents such as peptides into lipid phase of the dispersion for biodelivery of the agents for their typical purpose. Continuous methods for preparing the DNLF dispersions are also disclosed herein to include formation of a crude mill base and passing the base through a twin screw extruder. Dispersions disclosed herein can express a particle size of less than 150 nm under stable storage conditions, while forming lamellar structures after exposure to heat and/or evaporation of the aqueous components of the dispersion.

LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF

Resumen de: AU2023391361A1

Provided are aerosolized pharmaceutical compositions including aerosol particles, the aerosol particles comprising lipid nanoparticles (LNPs). Also provided herein are liquid pharmaceutical compositions for use in making aerosolized pharmaceutical compositions. Also provided herein are methods of administering the aerosolized pharmaceutical compositions. Also provided herein are kits including a lipid nanoparticle composition including one or more of a phospholipid, an ionizable lipid, a PEG-lipid, a sterol.

活性剤を含むタンパク質粒子、並びにその製造方法及び使用方法

Resumen de: AU2023272087A1

Described herein are particles including a protein and an active agent such as a particle comprising α-lactalbumin and tryptophan. Also described herein are methods of making and using particles that include a protein and an active agent.

多機能送達システム及びその使用

Resumen de: WO2023223307A1

The invention provides multifunctional system for the synchronized delivery of distinct immunoglobulins, in particular antibodies and antibody fragments to specific cancerous cells and tissues located outside of the brain. The multifunctional system is based on an inorganic core particle which is conjugated through a first polymeric linker to a first immunoglobulin; through a second polymeric linker to a second immunoglobulin; through a third polymeric linker to a penetration enhancing moiety; and to a fourth, monofunctional capping linker or spacer. Further provided are a process for preparation of the multifunctional system, pharmaceutical compositions comprising the multifunctional system and uses thereof in therapeutic and/or diagnostic methods.

がんを治療する方法

Resumen de: US2025064972A1

The present invention provides a conjugate comprising: (a) a cancer-targeting ligand, (b) a hydrophilic polymer of polyethylene glycol (PEG), polylactic acid (PLA), polylactic-co-glycolic acid (PLGA), or dextran, and (c) a flavonoid. The present invention also provides to a micelle nanoparticle composition comprising: (a) an outer shell comprising the conjugate, (b) an inner shell comprising oligomeric (−)-epigallocatechin gallate (OEGCG), and optionally (c) a cancer-treating molecule encapsulated in the inner shell. In one embodiment, the nanoparticle composition has at least 70% of the nanoparticles with a diameter between 20-500 nm or 50-300 nm, and one single major peak in the size distribution. The present invention further provides a method for treating cancer by administering an effective amount of the present nanoparticle composition to a subject. The cancer-targeting ligand targets the tumor and delivers active ingredients to tumor for treating cancer.

SELF-ASSEMBLING LIPID NANOPARTICLES FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS

Resumen de: AU2023378958A1

The present invention provides delivery system compositions comprising self- assembling lipid nanoparticles for targeted delivery of therapeutic or diagnostic agents to target cells. The particles are non-covalently attached to a lipidated antibody or antibody fragment which comprises an antibody or antibody fragment attached, via a peptide linker, to a lipidated peptide portion, wherein the antibody or antibody fragment is at the distal end from the nanoparticle.

MICROFLUIDIC ASSEMBLY OF RED BLOOD CELL (RBC) LIPIDS AND COMPONENTS FOR ENGINEERING EXTRACELLULAR VESICLES AND NANOPARTICLES

Resumen de: WO2025117906A1

Described herein are microfluidic approaches for the assembly of nanoparticles manufactured from isolated red blood cell (RBC) lipids and components. The engineered nanoparticles (e.g., vesicles) can be used to encapsulate cargo, including active agents such as proteins, nucleic acids (e.g., RNA), and other classes of therapeutic agents. Optionally, the vesicles can be further functionalized with targeting agents.

MIR-211 AND ACSL4 AS THERAPEUTIC AGENTS FOR CHILDHOOD CANCER MEDULLOBLASTOMAS

Resumen de: WO2025117832A1

Nanoparticles comprising miR-211 and their use for treating brain cancers, such as medulloblastomas, including pediatric medulloblastomas, are disclosed.

PROCESS FOR MANUFACTURING LIPID NANOPARTICLES

Resumen de: WO2025117969A1

The present application provides methods for manufacturing lipid nanoparticles. The present disclosure provides methods of preparing empty lipid nanoparticles (empty LNPs). The present disclosure provides methods of preparing loaded lipid nanoparticles (loaded LNPs) associated with a nucleic acid. Empty and loaded LNP compositions prepared by the subject methods are also provided. There is provided a homogeneous LNP composition of empty or loaded LNPs of particularly favorable average particle size and poly dispersity index.

COMPOUND COMPRISING EXTRACELLULAR VESICLES DERIVED FROM BIOLOGICAL MATERIAL NOT BELONGING TO THE ANIMAL KINGDOM AND ITS APPLICATIONS

Nº publicación: WO2025114909A1 05/06/2025

Solicitante:

CONSORZIO MELINDA SOC COOPERATIVA AGRICOLA [IT]
CONSORZIO MELINDA SOCIETA' COOPERATIVA AGRICOLA

Resumen de: WO2025114909A1

Compound for relieving inflammation in an organism comprising nanometer-sized extracellular vesicles (EVs) derived from biological material not belonging to the animal kingdom, but preferably belonging to the plant and fungi kingdoms, and loaded with a bioactive or a mixture of bioactives, preferably of plant origin.